KCNS1: A Potential Drug Target and Biomarker for Delayed-Rectifier K(+) Channel Alpha Subunit 1

Target Name: KCNS1

NCBI ID: G3787

KCNS1

Other Name(s): delayed-rectifier K(+) channel alpha subunit 1 | KCNS1 variant 1 | Delayed-rectifier K(+) channel alpha subunit 1 | Potassium voltage-gated channel modifier subfamily S member 1, transcript variant 1 | potassium voltage-gated channel modifier subfamily S member 1 | Potassium voltage-gated channel subfamily S member 1 | KV9.1 | Potassium voltage-gated channel delayed-rectifier protein S1 | voltage-gated potassium channel subunit Kv9.1 | Delayed-rectifier K+ channel alpha subunit 1 | Kv9.1 | Voltage-gated potassium channel subunit Kv9.1 | KCNS1_HUMAN | potassium voltage-gated channel, delayed-rectifier, subfamily S, member 1

KCNS1: A Potential Drug Target and Biomarker for Delayed-Rectifier K(+) Channel Alpha Subunit 1

Abstract:

KCNS1, the encoded gene for the delayed-rectifier K(+) channel alpha subunit 1, has been identified as a potential drug target and biomarker for various neurological and cardiovascular disorders. This subunit plays a crucial role in the regulation of intracellular K(+ ) ions, which are essential for various physiological processes, including muscle and nerve function, as well as cardiac function. The dysfunction of this subunit has been implicated in a range of neurodegenerative and cardiovascular diseases, including epilepsy, parkinson's disease, and heart failure.

Several studies have identified potential drug targets for KCNS1, including modulation of its expression and activity by various therapeutic agents. One of the most promising strategies is the use of small molecules, such as those derived from natural compounds, to modulate the activity of KCNS1 and improve its function.

In addition to its potential as a drug target, KCNS1 has also been identified as a potential biomarker for various neurological and cardiovascular disorders. The abnormal expression of this subunit has been observed in a variety of neurodegenerative and cardiovascular diseases, including Alzheimer's disease, Parkinson's disease , and heart failure. The potential utility of tracking the expression and activity of this subunit makes it an attractive candidate for diagnostic and therapeutic applications.

Overview:

KCNS1 is a subunit of the delayed-rectifier K(+) channel, which is a critical ion channel that plays a crucial role in the regulation of intracellular K(+) ions. The dysfunction of this subunit has been implicated in a range of neurodegenerative and cardiovascular diseases, including epilepsy, parkinson's disease, and heart failure.

In recent years, several studies have identified potential drug targets for KCNS1, including modulation of its expression and activity by various therapeutic agents. One of the most promising strategies is the use of small molecules, such as those derived from natural compounds, to modulate the activity of KCNS1 and improve its function.

In addition to its potential as a drug target, KCNS1 has also been identified as a potential biomarker for various neurological and cardiovascular disorders. The abnormal expression of this subunit has been observed in a variety of neurodegenerative and cardiovascular diseases, including Alzheimer's disease, Parkinson's disease , and heart failure. The potential utility of tracking the expression and activity of this subunit makes it an attractive candidate for diagnostic and therapeutic applications.

Structure and Function:

KCNS1 is a member of the K(+) channel subfamily of voltage-gated ion channels, which are responsible for the regulation of intracellular K(+) ions. These channels are characterized by the presence of an ion selectivity filter, which allows specific ions to pass through the channel and regulate the opening and closing of the channel. In the case of KCNS1, the channel is delayed rectifier, meaning that it allows K(+) ions to flow in, but at a slower rate than other channels.

The alpha subunit of KCNS1 is responsible for the regulation of the channel's activity and is characterized by the presence of several unique transmembrane domains, including an N-terminal alpha-helix, a central beta-sheet, and a C-terminal T-loop. The alpha subunit is responsible for the regulation of the channel's conductivity and for the modulation of its function by various factors, including changes in its phosphorylation state.

Dysfunction of KCNS1 has been implicated in a range of neurodegenerative and cardiovascular diseases, including epilepsy, parkinson's disease, and heart failure. Studies have shown that dysfunction of this subunit can lead to the mis regulation of intracellular K(+) ions, which can have a detrimental impact on various cellular processes and contribute to the development of these diseases.

Drug

Protein Name: Potassium Voltage-gated Channel Modifier Subfamily S Member 1

Functions: Potassium channel subunit that does not form functional channels by itself. Can form functional heterotetrameric channels with KCNB1 and KCNB2; modulates the delayed rectifier voltage-gated potassium channel activation and deactivation rates of KCNB1 and KCNB2 (PubMed:10484328)

The "KCNS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCNS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets